A Study of LY4065967 in Healthy Participants

{ "Study of LY4065967 in Healthy Participants", "This study is looking for healthy volunteers to compare three different forms of the drug LY4065967: a tablet and two types of capsules. The main goal is to understand how much of the drug gets into your bloodstream and how quickly, as well as to check for any side effects. Researchers will measure the drug's levels in your blood (pharmacokinetics or PK) at different times up to Day 17. To join, you must be between 18 and 55 years old, in good overall health, and have normal lab test results and an acceptable electrocardiogram (ECG). The study aims to enroll 36 participants, but its current recruitment status is unclear.", "design": "This is an interventional study involving 36 healthy participants. It compares three different formulations of LY4065967.", "commitments": "You would participate for about 7 weeks, including three separate 3-night stays in a Clinical Research Unit (CRU).", "compensation": "Not stated in the trial record.", "follow_up": "Drug levels will be measured up to Day 17 after administration.", }

Study design: Not specified.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

A Study of LY4065967 in Healthy Participants

Completed

PHASE1Ages 18–55InterventionalBasic science

Eli Lilly and Company

~36 participants

Updated 2026-08-19 on ClinicalTrials.gov

What's tested:LY4065967 TabletLY4065967 Formulated CapsuleLY4065967 Capsule

At a glance

Recruiting sites

0 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4065967

Measured over Baseline Up to Day 17

+2 more outcomes measured

Conditions

Healthy

Where it's being run

2 sites across 2 states

Florida1

Texas1

Study leadership

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.

Have clinical laboratory test results within normal reference range for the population or investigative site.

Have an electrocardiogram (ECG) at screening considered to be within acceptable limits by the investigator.

Have a body mass index within the range 18.0 to 35.0 kilograms per square meter (kg/m²) (inclusive).

Individuals assigned male at birth (AMAB) or assigned female at birth (AFAB) may participate in this trial.

Have venous access sufficient to allow for blood sampling.

Exclusion

Have a history of or current clinically significant medical conditions, including cardiovascular disease, electrolyte abnormalities, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disorders that, in the judgment of the investigator, could predispose to arrhythmia, pose a risk with study participation, significantly alter the absorption, metabolism, or elimination of the study drug, or interfere with the interpretation of study data.

Have systolic blood pressure of 140 millimeters of mercury (mmHg) or greater and diastolic blood pressure of 90 mmHg or greater at screening.

Have a history of clinically significant known allergies to LY4065967, related compounds, or any components of the formulation, or history of significant atopy.

Have a history of alcohol, opioids, stimulants or hallucinogens use disorder within 2 years prior to screening or a current use disorder by Diagnostic and Statistical Manual of Mental Disorders (APA 2013).

What this trial measures

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4065967Baseline Up to Day 17
PK: Area Under the Concentration Versus Time Curve from Time Zero to Time t [AUC(0- tlast)]Baseline Up to Day 17
PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity [AUC(0-∞)]Baseline Up to Day 17

Trialytics